11–28% of ATCs express programmed death ligand-1 (PD-L1) in either the inflammatory background or the tumor cells themselves, which explains the potential response of ATC to immunotherapies [22, 23]. This evidence concerns the gene CD274 and Ehlers-Danlos syndrome, musculocontractural type.